<DOC>
	<DOCNO>NCT02223494</DOCNO>
	<brief_summary>Study assess safety terbogrel open-label , long-term treatment medically stable improve patient primary pulmonary hypertension complete 12-week , double-blind randomize trial terbogrel ( protocol 528.19 )</brief_summary>
	<brief_title>Safety Terbogrel Patients With Primary Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Patients complete precede primary pulmonary hypertension , doubleblinded clinical trial terbogrel ( protocol 528.19 ) provide inform consent participate trial stable improve medical condition , opinion investigator enter study immediately upon completion precede doubleblind Trial 528.19 , enter study within one month complete precede trial long medical condition remain stable continue improve interim Development unstable medical condition follow completion precede clinical trial , investigator 's opinion , may worsen treatment terbogrel Premature discontinuation precede terbogrel clinical trial due adverse event reason Pregnant nursing woman , woman childbearing potential ( less one year postmenopausal surgically sterilize ) use adequate method birth control</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>